Disease Overview
Why HIV Treatment Demands Specialized BRA
HIV presents unique benefit-risk challenges spanning long-acting injectable formulations with novel PK profiles, ambitious cure research involving gene therapy and immunological interventions, and lifelong ART regimens where cumulative toxicity over 40+ years of treatment must be carefully monitored and managed.
Long-Acting Injectable Safety
Cabotegravir + rilpivirine (Cabenuva) represents a paradigm shift from daily oral ART to bimonthly injections, but introduces injection site reactions in up to 84% of patients, complex drug-drug interactions with rifamycins, and the critical risk of viral resistance emergence when injection windows are missed or delayed beyond the recommended dosing interval.
Cure Research Toxicity
HIV cure strategies carry substantial safety considerations: broadly neutralizing antibodies (VRC01, 3BNC117) with infusion reactions and immunogenicity, latency reversing agents (HDACi, PKC agonists) with systemic toxicity, gene therapy approaches including zinc finger nucleases and CRISPR-based editing with off-target effects, and allogeneic bone marrow transplantation with graft-versus-host disease and transplant-related mortality.
Lifelong ART Cumulative Toxicity
With treatment durations exceeding 40 years for many patients, cumulative ART toxicity is a critical BRA concern. Key signals include renal tubular dysfunction (tenofovir disoproxil fumarate), bone mineral density loss, metabolic syndrome and lipodystrophy, cardiovascular risk elevation with protease inhibitors, and neuropsychiatric effects including depression and vivid dreams with efavirenz. Long-term safety profiling requires specialized modeling.
Platform Capabilities
How ArcaScience Addresses HIV BRA
Our modules are configured with HIV antiretroviral data, drug resistance prediction models, long-acting PK modeling, and regulatory templates for ART and cure research submissions.
HIV Antiretroviral Data
3,200+ HIV clinical trials including ATLAS-2M, FLAIR, HPTN 083/084, and PARTNER studies. Comprehensive pharmacovigilance databases spanning FAERS, WHO VigiBase, and African cohort data covering populations with the highest global HIV burden. Real-world evidence across all 7 antiretroviral drug classes with resistance mutation databases.
Explore Data Engine →ARV-Specific AI Models
AI models for drug resistance prediction based on genotypic and phenotypic data, long-acting injectable pharmacokinetic modeling accounting for BMI, injection site, and adherence patterns, cumulative toxicity projection over decades-long treatment durations, and drug-drug interaction risk stratification for complex multi-drug regimens including TB co-treatment.
Explore AI Models →HIV Regulatory Outputs
PSURs for ART regimens covering all approved antiretroviral combinations, PrEP safety reports for cabotegravir and tenofovir-based prophylaxis across diverse populations, cure research IND submissions with novel safety monitoring frameworks, and post-marketing commitment reports aligned with FDA, EMA, and WHO prequalification requirements for global access programs.
Explore Outputs →HIV Intelligence
Platform Performance in HIV
HIV pharmacovigilance data points
Faster drug interaction signal detection
ARV-specific AI models deployed
HIV regulatory submissions supported
Case Evidence — HIV
Post-Marketing Surveillance for Long-Acting Injectable Cabotegravir + Rilpivirine
Challenge
A pharma company needed comprehensive post-marketing benefit-risk evaluation for their long-acting injectable cabotegravir + rilpivirine combination, with particular focus on injection site reaction characterization, pharmacokinetic tail effects, and the risk of drug resistance emergence in patients with missed or delayed injection windows.
Result
ArcaScience's AI models identified injection site reaction patterns correlated with injection technique and BMI 3.8x faster than traditional FAERS analysis, while reducing false positive resistance signals by 42% through improved differentiation between true virologic failure and transient viral blips in patients with delayed injections.
Faster ISR pattern identification
Reduction in false positive resistance signals
VP of Antiretroviral Safety
Global Pharma Company
Frequently Asked Questions